Lisa Mahnke

2.7k total citations · 2 hit papers
34 papers, 2.0k citations indexed

About

Lisa Mahnke is a scholar working on Oncology, Electrical and Electronic Engineering and Plant Science. According to data from OpenAlex, Lisa Mahnke has authored 34 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Electrical and Electronic Engineering and 9 papers in Plant Science. Recurrent topics in Lisa Mahnke's work include Polyomavirus and related diseases (16 papers), Full-Duplex Wireless Communications (9 papers) and Plant Virus Research Studies (8 papers). Lisa Mahnke is often cited by papers focused on Polyomavirus and related diseases (16 papers), Full-Duplex Wireless Communications (9 papers) and Plant Virus Research Studies (8 papers). Lisa Mahnke collaborates with scholars based in United States, Germany and France. Lisa Mahnke's co-authors include Howard L. Kaufman, Paul Nghiem, Shailender Bhatia, Isaac Brownell, Sandra P. D’Angelo, Kent C. Shih, Michèle Milella, Jochen H. Lorch, Omid Hamid and Anja von Heydebreck and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Cancer Research.

In The Last Decade

Lisa Mahnke

33 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

2016 933 citations Howard L. Kaufman, Jeffery S. Russell et al. The Lancet Oncology profile →
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

2018 327 citations Julius Strauss, Christopher R. Heery et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa Mahnke United States	14	1.5k	554	440	410	307	34	2.0k
Patrick Terheyden Germany	23	2.8k 1.9×	813 1.5×	662 1.5×	815 2.0×	398 1.3×	107	3.4k
Yanis Tolstov Germany	15	983 0.7×	647 1.2×	584 1.3×	42 0.1×	123 0.4×	22	1.6k
Riccardo Valdez United States	21	662 0.4×	63 0.1×	59 0.1×	375 0.9×	209 0.7×	50	3.0k
Sabrina Basso Italy	19	1.3k 0.9×	209 0.4×	53 0.1×	413 1.0×	387 1.3×	40	1.6k
Florent Grange France	35	1.9k 1.3×	56 0.1×	45 0.1×	534 1.3×	1.8k 5.8×	145	4.1k
Shih–Fan Kuan United States	24	672 0.5×	52 0.1×	35 0.1×	312 0.8×	269 0.9×	46	2.1k
Donald E. Tsai United States	32	1.8k 1.2×	54 0.1×	10 0.0×	431 1.1×	409 1.3×	117	3.3k
Andrea Baiocchini Italy	18	259 0.2×	42 0.1×	31 0.1×	186 0.5×	389 1.3×	52	1.1k
Amr S. Khaled United States	14	350 0.2×	80 0.1×	32 0.1×	141 0.3×	250 0.8×	24	1.0k
Kelly G. Paulson United States	27	3.0k 2.0×	2.2k 4.0×	1.9k 4.4×	231 0.6×	261 0.9×	56	3.2k

Countries citing papers authored by Lisa Mahnke

Since Specialization

Citations

This map shows the geographic impact of Lisa Mahnke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Mahnke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Mahnke more than expected).

Fields of papers citing papers by Lisa Mahnke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Mahnke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Mahnke. The network helps show where Lisa Mahnke may publish in the future.

Co-authorship network of co-authors of Lisa Mahnke

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Mahnke. A scholar is included among the top collaborators of Lisa Mahnke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Mahnke. Lisa Mahnke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Strauss, Julius, Christopher R. Heery, Jeffrey Schlom, et al.. (2018). Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Clinical Cancer Research. 24(6). 1287–1295. 327 indexed citations breakdown →

Kaufman, Howard L., et al.. (2018). Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences. Patient. 11(4). 439–449. 10 indexed citations

Kaufman, Howard L., Lisa Mahnke, Anja von Heydebreck, & Murtuza Bharmal. (2017). Association Between Tumour Lesion Size and Health-Related Quality of Life Outcomes in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Value in Health. 20(9). A455–A455. 1 indexed citations

Bharmal, Murtuza, et al.. (2017). Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. Health and Quality of Life Outcomes. 15(1). 247–247. 13 indexed citations

Kaufman, Howard L., Jeffery S. Russell, Omid Hamid, et al.. (2017). Abstract CT079: Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update. Cancer Research. 77(13_Supplement). CT079–CT079. 19 indexed citations

Shapiro, Irina M., H. Grote, Anja von Heydebreck, et al.. (2017). Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy.. Journal of Clinical Oncology. 35(15_suppl). 9557–9557. 3 indexed citations

Becker, Jürgen C., Eva Lorenz, Selma Ugurel, et al.. (2017). Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget. 8(45). 79731–79741. 66 indexed citations

Becker, Jan U., et al.. (2016). Evaluation of real world treatment outcomes in patients with metastatic merkel cell carcinoma (MCC) following second line chemotherapy. Annals of Oncology. 27. vi397–vi397. 6 indexed citations

Cowey, C. Lance, Lisa Mahnke, Janet L. Espirito, et al.. (2016). Real-World Outcomes of Patients with Metastatic Merkel Cell Carcinoma Treated with Second-Line or Later Chemotherapy in A Community Oncology Setting in The United States. Value in Health. 19(7). A717–A717. 4 indexed citations

10.

Kaufman, Howard L., Jeffery S. Russell, Omid Hamid, et al.. (2016). Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. The Lancet Oncology. 17(10). 1374–1385. 933 indexed citations breakdown →

11.

Kaufman, Howard L., et al.. (2016). Patient Perspectives on Merkel Cell Carcinoma (MCC) and Its Treatment with A Novel Agent (AVELUMAB): Findings From In-Depth Qualitative Patient Interviews. Value in Health. 19(7). A745–A745. 2 indexed citations

12.

Strauss, James, Jeffrey Schlom, Ravi A. Madan, et al.. (2016). A phase I, open-label, multiple-ascending-dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of M7824, a novel bifunctional fusion protein targeting the PD-L1 and TGF-β pathways, in patients with metastatic or locally advanced solid tumors. European Journal of Cancer. 69. S103–S104. 2 indexed citations

13.

Robertson, Sarah, et al.. (2014). Clinical drug‐drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P‐glycoprotein. The Journal of Clinical Pharmacology. 55(1). 56–62. 44 indexed citations

14.

Wang, Xiaodong, Marta Boffito, Jenny Zhang, et al.. (2011). Effects of the H ₂ -Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir With or Without Tenofovir in HIV-Infected Patients. AIDS Patient Care and STDs. 25(9). 509–515. 13 indexed citations

15.

Zhu, Li, Anna Persson, Lisa Mahnke, et al.. (2010). Effect of Low-Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple-Dose Atazanavir With Ritonavir in Healthy Subjects. The Journal of Clinical Pharmacology. 51(3). 368–377. 32 indexed citations

16.

Zhang, Jenny, Ellen Chung, Anna Persson, et al.. (2010). The Effect of Atazanavir/Ritonavir on the Pharmacokinetics of An Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Women. Antiviral Therapy. 16(2). 157–164. 34 indexed citations

17.

Mahnke, Lisa, Michael Belshan, & Lee Ratner. (2006). Analysis of HIV-2 Vpx by modeling and insertional mutagenesis. Virology. 348(1). 165–174. 13 indexed citations

18.

Mahnke, Lisa & David B. Clifford. (2006). Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation.. AIDS Research and Therapy. 3(1). 21–21. 11 indexed citations

19.

Belshan, Michael, Lisa Mahnke, & Lee Ratner. (2005). Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells. Virology. 346(1). 118–126. 37 indexed citations

20.

Reznikoff, William S., Archna Bhasin, D.R. Davies, et al.. (1999). Tn5: A Molecular Window on Transposition. Biochemical and Biophysical Research Communications. 266(3). 729–734. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact